https://www.selleckchem.com/pr....oducts/BIRB-796-(Dor
59; 95%CI 0.37-0.92), mainly driven by a reduction in bleeding (SHR 0.57; 95%CI 0.37-0.89). Exploratory analysis suggested greater reductions in bleeding with fondaparinux among patients undergoing transradial approach, revealing a significant interaction between treatment and vascular access on the multiplicative scale (P =0.0056), but not on an additive scale (P=0.457). Propensity-score-matching analysis yielded similar results. In contemporary management of NSTE-ACS, fondaparinux seems to provide a favorable net clinic